Ventolin (albuterol) / GSK - LARVOL DELTA

CAN A NEW PORTABLE-VALVED HOLDING CHAMBER (VHC) FOR USE ON THE GO DELIVER RELIEVER MEDICATION EFFECTIVELY AND IMPROVE VHC USE ADHERENCE? (CHEST 2025) - "This laboratory study compared the particle size distribution and therefore potential lung delivery of an albuterol MDI (Ventolin*) when administered alone versus the new portable VHC (AeroChamber2go*, A2GO) and a widely prescribed standard VHC (AeroChamber Plus* Flow-Vu*, ACFV)... This study showed that the new portable VHC produced similar FPM to the widely used standard size VHC, both being a little higher than the MDI alone if coordination was perfect. CLINICAL IMPLICATIONS: Such perfect actuation-inhalation coordination is known to be a challenge, hence the requirement in many cases to optimize consistent medication delivery through use of a VHC. Given the effective drug delivery demonstrated with the more portable AeroChamber2go* VHC in this study, it would appear to be a good choice to improve adherence to use of a VHC on the go for delivery of reliever medication."

Adherence

Formulary optimisation to reduce greenhouse gas emissions from inhalers: a retrospective audit of dispensing data (ERS 2025) - "Changing the preferred salbutamol MDI inhaler from Ventolin™ to Salamol™ significantly reduced GHG emissions. This demonstrates that formulary optimisation is an effective way to reduce the environmental impact of inhalers."

Retrospective data

Impact of Financial Incentives on Greener Inhaler Prescribing: A Retrospective Observational Study Using National Primary Care Data in England (ERS 2025) - "The financial incentives did not significantly reduce MDI use in England, where MDI use remains among the highest in Europe. The scheme was more effective when prescribing changes did not necessitate a device switch or in-person patient education, such as Ventolin to Salamol, which could be facilitated via remote communication (phone call, bulk text messages, or emails). These findings underscore the limitations of financial incentives alone in driving environmentally sustainable inhaler prescribing."

Observational data • Retrospective data • Genetic Disorders • Obesity

Hospital inhaler waste – what are we throwing away? (ERS 2025) - "For relievers without dose counters (Salamol and Ventolin) 47.5% (152/302) had >90% of doses remaining... A high proportion of inhalers returned to hospital pharmacies are either unused or almost full. The presence of a dose counter does not significantly impact upon this in hospital settings. 1."

Clinical • Respiratory Diseases

Balancing efficacy and portability: comparative in vitro/in vivo evaluation of MDI PLUS® versus AeroChamber2go™ spacers for aerosol delivery. (PubMed, J Asthma) - "In vitro, aerosol characteristics were assessed using an Andersen cascade impactor at 28.3 L/min with Ventolin® pMDI (5 puffs, 100 µg/puff); HPLC quantified drug deposition on each stage...Both the MDI PLUS® and the AeroChamber2go™ significantly enhanced pulmonary delivery and reduced systemic exposure compared to pMDI alone, while MDI PLUS® might potentially show a superior ease of use. These findings support the adoption of either device to optimize inhaler therapy."

Journal • Preclinical • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

COMPIS: Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment (clinicaltrials.gov) - P=N/A | N=18 | Completed | Sponsor: Vastra Gotaland Region | Enrolling by invitation ➔ Completed | Trial completion date: Dec 2025 ➔ Mar 2025 | Trial primary completion date: Dec 2025 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Musculoskeletal Diseases • Myositis

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=118 | Completed | Sponsor: AstraZeneca | Trial completion date: Oct 2025 ➔ Jun 2025 | Trial primary completion date: Oct 2025 ➔ Jun 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Assessment of a Valved Holding Chamber for Delivering Inhaled Medication Through a Tracheostomy Tube in a Tidal Breathing Model (ATS 2025) - " Albuterol (Ventolin™, 2-actuations) was delivered to the model via 2 different valved holding chambers (VHC, AEROTRACH PLUS® Anti-Static VHC and PARI® VORTEX® Tracheo Non-Electrostatic Holding Chamber) via 4.5mm or 8.0mm TTs... The choice of a metered-dose inhaler / VHC delivery system can significantly influence treatment efficacy. This study demonstrated that the AEROTRACH PLUS® Anti-Static VHC provided superior delivery of albuterol compared to the PARI® VORTEX® Tracheo Non-Electrostatic Holding Chamber (p<0.001). Optimizing lung deposition with the AEROTRACH PLUS® spacer may lead to faster symptom relief and potentially reduce the required number of actuations and cost of treatment."

Pediatrics • Pulmonary Disease • Respiratory Diseases

Patients with asthma reminded of the increased risk of severe asthma attacks from overusing blue inhalers (GOV.UK) - "The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding patients with asthma of the importance of using their preventer (anti-inflammatory) inhaler regularly as prescribed, and to avoid relying on their blue inhaler alone. This is because without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks. This reminder follows updates to product information and the National Institute for Health and Care Excellence (NICE) guidance for short-acting beta 2 agonists (SABAs), including salbutamol and terbutaline, which are used to relieve sudden asthma symptoms such as chest tightness, wheezing, coughing and breathlessness."

NICE • Asthma

Role of Salbutamol in the Management of Transient Tachypnea of the New Born (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: Khyber Teaching Hospital

New P1 trial

A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Children's Hospital and Institute of Child Health, Multan

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=102 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of a cardboard-based spacer for enhancing aerosol delivery from pressurized metered dose inhalers. (PubMed, J Asthma) - "The in-vitro part evaluated salbutamol's aerodynamic particle size distribution (APSD) after 0, 20, 50, 120, and 200 uses of Ventolin pressurized metered dose inhaler (pMDI) when connected to MDI Plus using an Andersen cascade impactor at an inhalation flow of 28.3 L/min...The amount deposited on the MDI and the hands of the patients after multiple storage in the MDI Plus box and uses was insignificant and within the allowed limits. The MDI Plus simultaneously can act as an pMDI packaging box and spacer, serving as a practical, affordable, and accessible alternative to traditionally commercially available plastic spacers, particularly in resource-limited settings."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Correct use of inhalers for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison chart: Some inhaled drugs for treatment of asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Pay to puff green: can NHS incentives change the prescribing practices? (BTS WM 2024) - "Comparator C2, involving salbutamol MDI swaps (mainly Ventolin to Salamol), showed significant improvement, with 8.11 new inhalers prescribed per 1,000 patients...When the inhaler swap did not necessitate introducing a new device and patient education (C2), the incentive was more effective. Despite the equal availability of the incentive, its uptake varied across England, potentially due to differences in guidelines and formularies ( figure 1 )."

Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Usability testing of a 3D-printed assistive device adaptor for a pressurized metered-dose inhaler (APSR 2024) - "Gripping force(s) required to depress the canister has significantly reduced by 73.5% (3.39kgfÀ0.90kgf) and 69.6% (2.73kgfÀ0.83kgf) for Ventolin and Atrovent respectively using Newton meter... 3D printed puff adaptors were effective in aiding patients with hand deficits in administering puffs."

Chronic Obstructive Pulmonary Disease • Immunology • Inflammatory Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Comparison of 3% Hypertonic Saline and Salbutamol in Children With Bronchiolitis (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: University of Health Sciences Lahore

New trial • Pulmonary Disease • Respiratory Diseases

MITCHELL: A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=102 | Not yet recruiting | Sponsor: AstraZeneca

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

VALUE OF CHEST PHYSIOTHERAPY WITH CONTINUOUS POSITIVE AIRWAY PRESSURE IN 5-YEAR-OLD CHILDREN: EFFECTS ON ATELECTASIS IN AMBULATORY HOSPITAL CARE (CHEST 2024) - "After one month of hospitalization in intensive care, she finally left the hospital with an inhaled treatment (Axotide, Ventolin) but remained short of breath and tired... A respiratory physiotherapy adapted to continuous positive airway pressure can significantly reduce atelectasis firmly established for many months in a young child."

Clinical • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Pulmonary Disease • Respiratory Diseases

PRISM: Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma (clinicaltrials.gov) - P4 | N=100 | Completed | Sponsor: GlaxoSmithKline | Recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Inhalation through two mini-spacer-like inhaler technique training devices: An in-vitro aerosol delivery comparative study (ERS 2024) - " 30 and 90 L/min inhalation flow rates over 2 and 5 sec were used to compare aerosol delivery of salbutamol from Ventolin Evohaler connected to FT and FTCR... The FT and FTCR delivered comparable salbutamol doses and fine particles (≤5 µm) under optimal and suboptimal inhalation through pMDI. The FTCR was privileged with lower throat deposition. Ultimately, these devices are intended to improve and maintain patients' correct pMDI use."

Preclinical • Respiratory Diseases

Does Use Of A Heat and Moisture Exchanger Affect pMDI Delivery to a Simulated Patient on Mechanical Ventilation (ERS 2024) - "5 actuations of Ventolin pMDI were delivered through 3 different delivery devices and a built-in port adapter in the circuit, followed by 6 complete breathing cycles... This study has shown that use of a bypass-type HME can allow delivery of medication to the patient. It also demonstrates that use of AeroChamber* VENT HC spacer could potentially reduce the carbon footprint by up to 4-fold compared to the alternative options. By maximizing the amount of each puff reaching the lungs the patient is likely to get relief sooner and reduce the number of puffs needed."

Clinical • Critical care • Respiratory Diseases

Drugs for COPD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tobacco Cessation